<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>A4810</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.fronterpagebillhead
	{mso-style-name:fronterpagebillhead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FPHangingAnAct, li.FPHangingAnAct, div.FPHangingAnAct
	{mso-style-name:FPHangingAnAct;
	mso-style-link:"FPHangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.4in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.FPHangingAnActChar
	{mso-style-name:"FPHangingAnAct Char";
	mso-style-link:FPHangingAnAct;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	letter-spacing:.2pt;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.0in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 1.3in 2.0in;}
div.WordSection3
	{page:WordSection3;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuBill><a name=bpuFrontPg></a>ASSEMBLY, No. 4810 </p>

<p class=bpuWpGraphic><b><span style='font-size:32.0pt;line-height:120%;
font-family:"Arial",sans-serif;letter-spacing:0pt'>STATE OF NEW JERSEY</span></b></p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>INTRODUCED SEPTEMBER 19, 2024</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:11.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Assemblyman  LOUIS D. GREENWALD</p>

<p class=bpuSponsor>District 6 (Burlington and Camden)</p>

<p class=bpuSponsor>Assemblyman  REGINALD W. ATKINS</p>

<p class=bpuSponsor>District 20 (Union)</p>

<p class=bpuSponsor>Assemblywoman  SHANIQUE SPEIGHT</p>

<p class=bpuSponsor>District 29 (Essex and Hudson)</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>Co-Sponsored by:</p>

<p class=bpuSponsor>Assemblywomen Donlon and Peterpaul</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Requires NJ FamilyCare reimbursement for pediatric
medication management services provided for certain children by licensed
pharmacist. </p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     As introduced.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif;
letter-spacing:.2pt'><br clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=HangingAnAct style='line-height:150%'><span class=BillHead>An Act</span><span
class=HangingAnActChar> </span>concerning medication management services for
certain NJ FamilyCare enrollees and amending P.L.1968, c.413 and P.L.2003,
c.280.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     1.    Section 6 of P.L.1968,
c.413 (C.30:4D-6) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     6.    a.  Subject to the
requirements of Title XIX of the federal Social Security Act, the limitations
imposed by this act and by the rules and regulations promulgated pursuant
thereto, the department shall provide medical assistance to qualified
applicants, including authorized services within each of the following
classifications:</p>

<p class=MsoNormal style='line-height:150%'>     (1) Inpatient hospital
services</p>

<p class=MsoNormal style='line-height:150%'>     (2) Outpatient hospital
services;</p>

<p class=MsoNormal style='line-height:150%'>     (3) Other laboratory and X-ray
services;</p>

<p class=MsoNormal style='line-height:150%'>     (4) (a) Skilled nursing or
intermediate care facility services;</p>

<p class=MsoNormal style='line-height:150%'>     (b) Early and periodic
screening and diagnosis of individuals who are eligible under the program and
are under age 21, to ascertain their physical or mental health status and the
health care, treatment, and other measures to correct or ameliorate defects and
chronic conditions discovered thereby, as may be provided in regulation of the
Secretary of the federal Department of Health and Human Services and approved
by the commissioner;</p>

<p class=MsoNormal style='line-height:150%'>     (5) Physician's services
furnished in the office, the patient's home, a hospital, a skilled nursing, or
intermediate care facility or elsewhere.</p>

<p class=MsoNormal style='line-height:150%'>     As used in this subsection,
&quot;laboratory and X-ray services&quot; includes HIV drug resistance testing,
including, but not limited to, genotype assays that have been cleared or
approved by the federal Food and Drug Administration, laboratory developed
genotype assays, phenotype assays, and other assays using phenotype prediction
with genotype comparison, for persons diagnosed with HIV infection or AIDS.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Subject to the
limitations imposed by federal law, by this act, and by the rules and
regulations promulgated pursuant thereto, the medical assistance program may be
expanded to include authorized services within each of the following
classifications:</p>

<p class=MsoNormal style='line-height:150%'>     (1) Medical care not included
in subsection a.(5) above, or any other type of remedial care recognized under
State law, furnished by licensed practitioners within the scope of their
practice, as defined by State law;</p>

<p class=MsoNormal style='line-height:150%'>     (2) Home health care services;</p>

<p class=MsoNormal style='line-height:150%'>     (3) Clinic services;</p>

<p class=MsoNormal style='line-height:150%'>     (4) Dental services;</p>

<p class=MsoNormal style='line-height:150%'>     (5) Physical therapy and
related services;</p>

<p class=MsoNormal style='line-height:150%'>     (6) Prescribed drugs,
dentures, and prosthetic devices; and eyeglasses prescribed by a physician
skilled in diseases of the eye or by an optometrist, whichever the individual
may select;</p>

<p class=MsoNormal style='line-height:150%'>     (7) Optometric services;</p>

<p class=MsoNormal style='line-height:150%'>     (8) Podiatric services;</p>

<p class=MsoNormal style='line-height:150%'>     (9) Chiropractic services;</p>

<p class=MsoNormal style='line-height:150%'>     (10) Psychological services;</p>

<p class=MsoNormal style='line-height:150%'>     (11) Inpatient psychiatric
hospital services for individuals under 21 years of age, or under age 22 if
they are receiving such services immediately before attaining age 21;</p>

<p class=MsoNormal style='line-height:150%'>     (12) Other diagnostic, screening,
preventative, and rehabilitative services, and other remedial care;</p>

<p class=MsoNormal style='line-height:150%'>     (13) Inpatient hospital
services, nursing facility services, and immediate care facility services for
individuals 65 years of age or over in an institution for mental diseases;</p>

<p class=MsoNormal style='line-height:150%'>     (14) Intermediate care
facility services;</p>

<p class=MsoNormal style='line-height:150%'>     (15) Transportation services;</p>

<p class=MsoNormal style='line-height:150%'>     (16) Services in connection
with the inpatient or outpatient treatment or care of substance use disorder,
when the treatment is prescribed by a physician and provided in a licensed
hospital or in a narcotic and substance use disorder treatment center approved
by the Department of Health pursuant to P.L.1970, c.334 (C.26:2G-21 et. seq.)
and whose staff includes a medical director, and limited those services
eligible for federal financial participation under Title XIX of the federal
Social Security Act;</p>

<p class=MsoNormal style='line-height:150%'>     (17) Any other medical care
and any other type of remedial care recognized under State law, specified by
the Secretary of the federal Department of Health and Human Services, and
approved by the commissioner;</p>

<p class=MsoNormal style='line-height:150%'>     (18) Comprehensive maternity
care, which may include: the basic number of prenatal and postpartum visits
recommended by the American College of Obstetrics and Gynecology; additional
prenatal and postpartum visits that are medically necessary; necessary
laboratory, nutritional assessment and counseling, health education, personal
counseling, managed care, outreach, and follow-up services; treatment of
conditions which may complicate pregnancy doula care; and physician or
certified nurse midwife delivery services.  For the purposes of this paragraph,
&quot;doula&quot; means a trained professional who provides continuous
physical, emotional, and informational support to a mother before, during, and
shortly after childbirth, to help her to achieve the healthiest, most
satisfying experience possible;</p>

<p class=MsoNormal style='line-height:150%'>     (19) Comprehensive pediatric
care, which may include: ambulatory, preventive, and primary care health
services.  The preventive services shall include, at a minimum, the basic
number of preventive visits recommended by the American Academy of Pediatrics;</p>

<p class=MsoNormal style='line-height:150%'>     (20) Services provided by a
hospice which is participating in the Medicare program established pursuant to
Title XVIII of the Social Security Act, Pub.L.89-97 (42 U.S.C. s.1395 et
seq.).  Hospice services shall be provided subject to approval of the Secretary
of the federal Department of Health and Human Services for federal
reimbursement;</p>

<p class=MsoNormal style='line-height:150%'>     (21) Mammograms, subject to
approval of the Secretary of the federal Department of Health and Human
Services for federal reimbursement, including one baseline mammogram for women
who are at least 35 but less than 40 years of age; one mammogram examination
every two years or more frequently, if recommended by a physician, for women
who are at least 40 but less than 50 years of age; and one mammogram
examination every year for women age 50 and over;</p>

<p class=MsoNormal style='line-height:150%'>     (22) Upon referral by a
physician, advanced practice nurse, or physician assistant of a person who has
been diagnosed with diabetes, gestational diabetes, or pre-diabetes, in accordance
with standards adopted by the American Diabetes Association:</p>

<p class=MsoNormal style='line-height:150%'>     (a) Expenses for diabetes
self-management education or training to ensure that a person with diabetes,
gestational diabetes, or pre-diabetes can optimize metabolic control, prevent
and manage complications, and maximize quality of life.  Diabetes
self-management education shall be provided by an in-State provider who is:</p>

<p class=MsoNormal style='line-height:150%'>     (i) a licensed, registered, or
certified health care professional who is certified by the National
Certification Board of Diabetes Educators as a Certified Diabetes Educator, or
certified by the American Association of Diabetes Educators with a Board
Certified-Advanced Diabetes Management credential, including, but not limited
to: a physician, an advanced practice or registered nurse, a physician
assistant, a pharmacist, a chiropractor, a dietitian registered by a nationally
recognized professional association of dietitians, or a nutritionist holding a
certified nutritionist specialist (CNS) credential from the Board for Certification
of Nutrition Specialists; or</p>

<p class=MsoNormal style='line-height:150%'>     (ii) an entity meeting the
National Standards for Diabetes Self-Management Education and Support, as
evidenced by a recognition by the American Diabetes Association or
accreditation by the American Association of Diabetes Educators;</p>

<p class=MsoNormal style='line-height:150%'>     (b) Expenses for medical
nutrition therapy as an effective component of the person's overall treatment
plan upon a: diagnosis of diabetes, gestational diabetes, or pre-diabetes;
change in the beneficiary's medical condition, treatment, or diagnosis; or
determination of a physician, advanced practice nurse, or physician assistant
that reeducation or refresher education is necessary.  Medical nutrition
therapy shall be provided by an in-State provider who is a dietitian registered
by a nationally-recognized professional association of dietitians, or a
nutritionist holding a certified nutritionist specialist (CNS) credential from
the Board for Certification of Nutrition Specialists, who is familiar with the
components of diabetes medical nutrition therapy;</p>

<p class=MsoNormal style='line-height:150%'>     (c) For a person diagnosed
with pre-diabetes, items and services furnished under an in-State diabetes
prevention program that meets the standards of the National Diabetes Prevention
Program, as established by the federal Centers for Disease Control and
Prevention; and</p>

<p class=MsoNormal style='line-height:150%'>     (d) Expenses for any medically
appropriate and necessary supplies and equipment recommended or prescribed by a
physician, advanced practice nurse, or physician assistant for the management
and treatment of diabetes, gestational diabetes, or pre-diabetes, including,
but not limited to: equipment and supplies for self-management of blood
glucose; insulin pens; insulin pumps and related supplies; and other insulin
delivery devices;</p>

<p class=MsoNormal style='line-height:150%'>     (23) Expenses incurred for the
provision of group prenatal services to a pregnant woman, provided that:</p>

<p class=MsoNormal style='line-height:150%'>     (a) the provider of such
services, which shall include, but not be limited to, a federally qualified
health center or a community health center operating in the State:</p>

<p class=MsoNormal style='line-height:150%'>     (i) is a site accredited by the
Centering Healthcare Institute, or is a site engaged in an active
implementation contract with the Centering Healthcare institute, that utilizes
the Centering Pregnancy model; and</p>

<p class=MsoNormal style='line-height:150%'>     (ii) incorporates the
applicable information outlined in any best practices manual for prenatal and
postpartum maternal care developed by the Department of Health into the
curriculum for each group prenatal visit;</p>

<p class=MsoNormal style='line-height:150%'>     (b) each group prenatal care
visit is at least 1.5 hours in duration, with a. minimum of two women and a
maximum of 20 women in participation; and</p>

<p class=MsoNormal style='line-height:150%'>     (c) no more than 10 group
prenatal care visits occur per pregnancy.  As used in this paragraph,
&quot;group prenatal care services&quot; means a series of prenatal care visits
provided in a group setting which are based upon the Centering Pregnancy model
developed by the Centering Healthcare Institute and which include health
assessments, social and clinical support, and educational activities;</p>

<p class=MsoNormal style='line-height:150%'>     (24) Expenses incurred for the
provision of pasteurized donated human breast milk, which shall include human
milk fortifiers if indicated in a medical order provided by a licensed medical
practitioner, to an infant under the age of six months; provided that the milk
is obtained from a human milk bank that meets quality guidelines established by
the Department of Health and a licensed medical practitioner has issued a
medical order for the infant under at least one of the following circumstances:</p>

<p class=MsoNormal style='line-height:150%'>     (a) the infant is medically or
physically unable to receive maternal breast milk or participate in breast
feeding, or the infant's mother is medically or physically unable to produce
maternal breast milk in sufficient quantities or participate in breast feeding
despite optimal lactation support; or</p>

<p class=MsoNormal style='line-height:150%'>     (b) the infant meets any of
the following conditions:</p>

<p class=MsoNormal style='line-height:150%'>     (i) a body weight below
healthy levels, as determined by the licensed medical practitioner issuing the
medical order for the infant;</p>

<p class=MsoNormal style='line-height:150%'>     (ii) the infant has a
congenital or acquired condition that places the infant at a high risk for
development of necrotizing enterocolitis; or </p>

<p class=MsoNormal style='line-height:150%'>     (iii) the infant has a
congenital or acquired condition that may benefit from the use of donor breast
milk and human milk fortifiers, as determined by the Department of Health; </p>

<p class=MsoNormal style='line-height:150%'>     (25) Comprehensive tobacco
cessation benefits to an individual who is 18 years of age or older, or who is
pregnant.  Coverage shall include: brief and high intensity individual
counseling, brief and high intensity group counseling, and telemedicine as
defined by section 1 of P.L.2017, c.117 (C.45:1-61); all medications approved
for tobacco cessation by the U.S. Food and Drug Administration; and other
tobacco cessation counseling recommended by the Treating Tobacco Use and
Dependence Clinical Practice Guideline issued by the U.S. Public Health
Service.  Notwithstanding the provisions of any other law, rule, or regulation
to the contrary, and except as otherwise provided in this section:</p>

<p class=MsoNormal style='line-height:150%'>     (a) Information regarding the
availability of the tobacco cessation services described in this paragraph
shall be provided to all individuals authorized to receive the tobacco
cessation services pursuant to this paragraph at the following times: no later
than 90 days after the effective date of P.L.2019, c.473: upon the
establishment of an individual's eligibility for medical assistance; and upon
the redetermination of an individual's eligibility for medical assistance;</p>

<p class=MsoNormal style='line-height:150%'>     (b) The following conditions
shall not be imposed on any tobacco cessation services provided pursuant to
this paragraph: copayments or any other forms of cost-sharing, including
deductibles; counseling requirements for medication; stepped care therapy or
similar restrictions requiring the use of one service prior to another; limits
on the duration of services; or annual or lifetime limits on the amount,
frequency, or cost of services, including, but not limited to, annual or
lifetime limits on the number of covered attempts to quit; and</p>

<p class=MsoNormal style='line-height:150%'>     (c) Prior authorization
requirements shall not be imposed on any tobacco cessation services provided
pursuant to this paragraph except in the following circumstances where prior
authorization may be required: for a treatment that exceeds the duration
recommended by the most recently published United States Public Health Service
clinical practice guidelines on treating tobacco use and dependence; or for
services associated with more than two attempts to quit within a 12-month
period;</p>

<p class=MsoNormal style='line-height:150%'>     (26) Provided that there is
federal financial participation available, benefits for expenses incurred in
conducting a colorectal cancer screening in accordance with United States
Preventive Services Task Force recommendations.  The method and frequency of
screening to be utilized shall be in accordance with the most recent published
recommendations of the United States Preventive Services Task Force and as
determined medically necessary by the covered person's physician, in
consultation with the covered person.</p>

<p class=MsoNormal style='line-height:150%'>     No deductible, coinsurance,
copayment, or any other cost-sharing requirement shall be imposed for a
colonoscopy performed following a positive result on a non-colonoscopy,
colorectal cancer screening test recommended by the United States Preventive
Services Task Force; <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>and<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b></p>

<p class=MsoNormal style='line-height:150%'>     (27) (a) Within 24 months of
the effective date of P.L.2023, c.187 (C.30:4D-6u et seq.), and conditional on
the receipt of all necessary federal approvals and the securing of federal
financial participation pursuant to section 2 of P.L.2023, c.187 (C.30:4D-6u),
community-based palliative care benefits which shall include, but not be
limited to, all of the following:</p>

<p class=MsoNormal style='line-height:150%'>     (i) specialized medical care
and emotional and spiritual support for beneficiaries with serious advanced
illnesses; </p>

<p class=MsoNormal style='line-height:150%'>     (ii) relief of symptoms, pain,
and stress of serious illness;</p>

<p class=MsoNormal style='line-height:150%'>     (iii) improvement of quality
of life for both the beneficiary and the beneficiary's family; and</p>

<p class=MsoNormal style='line-height:150%'>     (iv) appropriate care for any
age and for any stage of serious illness, along with curative treatment. </p>

<p class=MsoNormal style='line-height:150%'>     (b) Benefits provided under
this paragraph shall include, but shall not be limited to, services provided by
a hospice pursuant to paragraph (20) of subsection b. of this section, provided
that:</p>

<p class=MsoNormal style='line-height:150%'>     (i) hospice services may be
provided at the same time that curative treatment is available, to the extent
that services are not duplicative;</p>

<p class=MsoNormal style='line-height:150%'>     (ii) hospice services may be
provided to beneficiaries whose conditions may result in death, regardless of
the estimated length of the beneficiary's remaining period of life; and </p>

<p class=MsoNormal style='line-height:150%'>     (iii) the Division of Medical
Assistance and Health Services in the Department of Human Services may include
any other service deemed appropriate under the benefits provided under this
paragraph.</p>

<p class=MsoNormal style='line-height:150%'>     (c) Providers authorized to
deliver benefits provided under this paragraph shall include Medicaid-approved
licensed hospice agencies, Medicaid-approved home health agencies licensed to
provide hospice care, and other Medicaid-approved licensed health care
providers.</p>

<p class=MsoNormal style='line-height:150%'>     (d) Nothing in this paragraph
shall be construed to result in the elimination or reduction of covered
benefits or services under the Medicaid program.</p>

<p class=MsoNormal style='line-height:150%'>     (e) This paragraph shall not
affect a beneficiary's eligibility to receive, concurrently with services
provided for in this paragraph, any services, including home health services,
for which the beneficiary would have been eligible in the absence of this
paragraph, to the extent that services are not duplicative <u>; and</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(28) (a) Comprehensive
medication management services for a medically complex pediatric patient when
provided by a licensed clinical pharmacist, which services shall include:</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(i)   comprehensive reviews,
conducted on a schedule to be determined in collaboration with the patients team
of healthcare providers, of the patients prescription medications,
over-the-counter medications, vitamins, and nutritional supplements;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(ii)  development and
implementation of patient-specific medication action plans;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(iii) ongoing monitoring of
the patients adherence to the patient-specific medication action plan;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(iv) follow-up consultations
and services as needed to ensure the efficacy and safety of the patient-specific
medication action plan; and</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(v)  any other
comprehensive medication management services deemed necessary by the division
and the Board of Pharmacy for the appropriate care of a medically complex
pediatric patient.</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(b)  The division and the
Board of Pharmacy shall designate the educational, training, and credentialing
requirements that licensed clinical pharmacists shall satisfy in order to be
authorized to provide comprehensive medication management services under this
paragraph.</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(c)   Notwithstanding the
provisions of P.L.2003, c.280 (C.45:14-40 et seq.), a licensed clinical
pharmacist who satisfies the requirements of this paragraph shall not be
required to enter into a written agreement with a licensed physician in order
to provide comprehensive medication management services for a medically complex
pediatric patient.</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(d)  The division shall
enter into value-based reimbursement contracts with licensed clinical
pharmacists for the provision of</u> <u>comprehensive medication management
services for medically complex pediatric patients;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(e)   The division shall
establish a quality assurance program in order to monitor and evaluate the outcomes
and efficacy of the comprehensive medication management services provided for medically
complex pediatric patients, and ensure that the services provided align with
the divisions value-based payment strategies.</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(f)   As used in this
paragraph:</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>Board of Pharmacy means
the New Jersey State Board of Pharmacy of the Division of Consumer Affairs in
the Department of Law and Public Safety.</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>Clinical pharmacist means
a licensed pharmacist who has completed a clinical residency or a Board of
Pharmacy Specialties certification to acquire expertise in the therapeutic use
of medications to ensure optimal patient health outcomes.  Clinical pharmacists
work as part of a patients healthcare professional team to provide medication
therapy evaluations and recommendations to patients and healthcare
professionals.  </u></p>

<p class=MsoNormal style='line-height:150%'>     <u>Comprehensive medication
management services means a standard of care that ensures that a patients
medications, including prescription and nonprescription medications, vitamins,
or nutritional supplements, are individually assessed to determine whether each
medication is: appropriate for the patient, effective for the patients medical
condition, safe given the patients comorbidities and other medications being
taken, and able to be taken by the patient as intended.  Comprehensive
medication management services are provided by a clinical pharmacist as part of
a patients healthcare professional team.</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>Division means the
Division of Medical Assistance and Health Services in the Department of Human
Services</u> .</p>

<p class=MsoNormal style='line-height:150%'>     c.    Payments for the
foregoing services, goods and supplies furnished pursuant to this act shall be
made to the extent authorized by this act, the rules and regulations
promulgated pursuant thereto and, where applicable, subject to the agreement of
insurance provided for under this act.  The payments shall constitute payment
in full to the provider on behalf of the recipient.  Every provider making a
claim for payment pursuant to this act shall certify in writing on the claim
submitted that no additional amount will be charged to the recipient, the recipient's
family, the recipient's representative or others on the recipient's behalf for
the services, goods, and supplies furnished pursuant to this act.</p>

<p class=MsoNormal style='line-height:150%'>     No provider whose claim for
payment pursuant to this act has been denied because the services, goods, or
supplies were determined to be medically unnecessary shall seek reimbursement
form the recipient, his family, his representative or others on his behalf for
such services, goods, and supplies provided pursuant to this act; provided,
however, a provided may seek reimbursement from a recipient for services,
goods, or supplies not authorized by this act, if the recipient elected to
receive the services, goods or supplies with the knowledge that they were not
authorized.</p>

<p class=MsoNormal style='line-height:150%'>     d.    Any individual eligible
for medical assistance (including drugs) may obtain such assistance from any
person qualified to 33 perform the service or services required (including an
organization which provides such services, or arranges for their availability
on a prepayment basis), who undertakes to provide the individual such services.</p>

<p class=MsoNormal style='line-height:150%'>     No copayment or other form of
cost-sharing shall be imposed on any individual eligible for medical
assistance, except as mandated by federal law as a condition of federal
financial participation.</p>

<p class=MsoNormal style='line-height:150%'>     e.    Anything in this act to
the contrary notwithstanding, no payments for medical assistance shall be made
under this act with respect to care or services for any individual who:</p>

<p class=MsoNormal style='line-height:150%'>     (1) Is an inmate of a public
institution (except as a patient in a medical institution); provided, however,
that an individual who is otherwise eligible may continue to receive services
for the month in which he becomes an inmate, should the commissioner determine
to expand the scope of Medicaid eligibility to include such an individual, subject
to the limitations imposed by federal law and regulations, or</p>

<p class=MsoNormal style='line-height:150%'>     (2) Has not attained 65 years
of age and who is a patient in an institution for mental diseases, or</p>

<p class=MsoNormal style='line-height:150%'>     (3) Is over 21 years of age
and who is receiving inpatient psychiatric hospital services in a psychiatric
facility; provided, however, that an individual who was receiving such services
immediately prior to attaining age 21 may continue to receive such services
until the individual reaches age 22.  Nothing in this subsection shall prohibit
the commissioner from extending medical assistance to all eligible persons
receiving inpatient psychiatric services; provided that there is federal
financial participation available.</p>

<p class=MsoNormal style='line-height:150%'>     f.  (1) A third party as
defined in section 3 of P.L.1968, c.413 (C.30:4D-3) shall not consider a
person's eligibility for Medicaid in this or another state when determining the
person's eligibility for enrollment or the provision of benefits by that third
party.</p>

<p class=MsoNormal style='line-height:150%'>     (2) In addition, any provision
in a contract of insurance, health benefits plan, or other health care coverage
document, will, trust, agreement, court order, or other instrument which
reduces or excludes coverage or payment for health care-related goods and
services to or for an individual because of that individual's actual or
potential eligibility for or receipt of Medicaid benefits shall be null and
void, and no payments shall be made under this act as a result of any such
provision.</p>

<p class=MsoNormal style='line-height:150%'>     (3) Notwithstanding any
provision of law to the contrary, the provisions of paragraph (2) of this
subsection shall not apply to a trust agreement that is established pursuant to
42 U.S.C. s.1396p(d)(4)(A) or (C) to supplement and augment assistance provided
by government entities to a person who is disabled as defined in section 1614(a)(3)
of the federal Social Security Act (42 31 U.S.C. s.1382c (a)(3)).</p>

<p class=MsoNormal style='line-height:150%'>     g.    The following services
shall be provided to eligible medically needy individuals as follows:</p>

<p class=MsoNormal style='line-height:150%'>     (1) Pregnant women shall be
provided prenatal care and delivery services and postpartum care, including the
services cited in subsections a.(1), (3), and (5) of this section and
subsections b.(1)-(10), (12), (15), and (17) of this section, and nursing
facility services cited in subsection b.(13) of this section.</p>

<p class=MsoNormal style='line-height:150%'>     (2) Dependent children shall
be provided with services cited in subsections a.(3) and (5) of this section
and subsections b.(1), (2), (3), (4), (5), (6), (7), (10), (12), (15), and (17)
of this section, and nursing facility services cited in subsection b.(13) of
this section.</p>

<p class=MsoNormal style='line-height:150%'>     (3) Individuals who are 65
years of age or older shall be provided with services cited in subsections
a.(3) and (5) of this section and subsections b.(1)-(5), (6) excluding
prescribed drugs, (7), (8), (10), (12), (15), and (17) of this section, and
nursing facility services cited in subsection b.(13) of this section.</p>

<p class=MsoNormal style='line-height:150%'>     (4) Individuals who are blind
or disabled shall be provided with services cited in subsections a.(3) and (5)
of this section and subsections b.(1)-(5), (6) excluding prescribed drugs, (7),
(8), (10), 3 (12), (15), and (17) of this section, and nursing facility
services cited in subsection b.(13) of this section.</p>

<p class=MsoNormal style='line-height:150%'>     (5) (a) Inpatient hospital
services, subsection a.(1) of this section, shall only be provided to eligible
medically needy individuals, other than pregnant women, if the federal
Department of Health and Human Services discontinues the State's waiver to
establish inpatient hospital reimbursement rates for the Medicare and Medicaid
programs under the authority of section 601(c)(3) of the Social Security Act
Amendments of 1983, Pub.L.98-21 (42 U.S.C. s.1395ww(c)(5)).  Inpatient hospital
services may be extended to other eligible medically needy individuals if the
federal Department of Health and Human Services directs that these services be included.</p>

<p class=MsoNormal style='line-height:150%'>     (b) Outpatient hospital
services, subsection a.(2) of this section, shall only be provided to eligible
medically needy individuals if the federal Department of Health and Human
Services discontinues the State's waiver to establish outpatient hospital
reimbursement rates for the Medicare and Medicaid programs under the authority
of section 601(c)(3) of the Social Security Amendments of 1983, Pub.L.98-21 (42
U.S.C. s.1395ww(c)(5)).  Outpatient hospital services may be extended to all or
to certain medically needy individuals if the federal Department of Health and
Human Services directs that these services be included.  However, the use of
outpatient hospital services shall be limited to clinic services and to
emergency room services for injuries and significant acute medical conditions.</p>

<p class=MsoNormal style='line-height:150%'>     (c) The division shall monitor
the use of inpatient and outpatient hospital services by medically needy
persons.</p>

<p class=MsoNormal style='line-height:150%'>     h.    In the case of a
qualified disabled and working individual pursuant to section h6408 of
Pub.L.101-239 (42 U.S.C. s.1396d), the only medical assistance provided under
this act shall be the payment of premiums for Medicare part A under 42 U.S.C.
ss.1395i-2 and 1395r.</p>

<p class=MsoNormal style='line-height:150%'>     i.     In the case of a
specified low-income Medicare beneficiary pursuant to 42 U.S.C. s.1396a(a)10(E)iii,
the only medical assistance provided under this act shall be the payment of
premiums for Medicare part B under 42 U.S.C. s.1395r as provided for in 42
U.S.C. s.1396d(p)(3)(A)(ii).</p>

<p class=MsoNormal style='line-height:150%'>     j.     In the case of a
qualified individual pursuant to 42 U.S.C. s.1396a(aa), the only medical
assistance provided under this act shall be payment for authorized services
provided during the period in which the individual requires treatment for
breast or cervical cancer, in accordance with criteria established by the
commissioner.</p>

<p class=MsoNormal style='line-height:150%'>     k.    In the case of a
qualified individual pursuant to 42 U.S.C. s.1396a(ii), the only medical
assistance provided under this act shall be payment for family planning
services and supplies as described at 42 U.S.C. s.1396d(a)(4)(C), including
medical diagnosis and treatment services that are provided pursuant to a family
planning service in a family planning setting.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2023, c.187, s.1).</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     2.    Section 9 of P.L.2003,
c.280 (C.45:14-48) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     9.  a.  The board shall be
responsible for the control and regulation of the practice of pharmacy in this
State including, but not limited to, the following:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  The licensing by
examination or by license transfer of applicants who are qualified to engage in
the practice of pharmacy under the provisions of this act;</p>

<p class=MsoNormal style='line-height:150%'>     (2)  The renewal of licenses
to engage in the practice of pharmacy;</p>

<p class=MsoNormal style='line-height:150%'>     (3)  The establishment and
enforcement of professional standards and rules of conduct of pharmacists
engaged in the practice of pharmacy;</p>

<p class=MsoNormal style='line-height:150%'>     (4)  The establishment of
requirements for pharmacists to engage in collaborative practice;</p>

<p class=MsoNormal style='line-height:150%'>     (5)  The establishment of
requirements jointly promulgated with the State Board of Medical Examiners for
pharmacists to administer drugs directly to patients;</p>

<p class=MsoNormal style='line-height:150%'>     (6)  The enforcement of those
provisions of this act relating to the conduct or competence of pharmacists
practicing in this State, and the suspension, revocation, failure to renew or
restriction of licenses to engage in the practice of pharmacy pursuant to the
provisions of P.L.1978, c.73 (C.45:1-14 et seq.);</p>

<p class=MsoNormal style='line-height:150%'>     (7)  The regulation of
pharmacy practiced through any technological means;</p>

<p class=MsoNormal style='line-height:150%'>     (8)  The regulation and
control of automated medication systems and automated medication devices within
or outside of pharmacy practice sites;</p>

<p class=MsoNormal style='line-height:150%'>     (9)  The right to seize any
drugs and devices found by the board to constitute an imminent danger to the
public health and welfare;</p>

<p class=MsoNormal style='line-height:150%'>     (10) The establishment of
minimum specifications for record keeping, prescription and patient profile
record maintenance, pharmacy practice sites including, but not limited to, the
physical premises, technical equipment, environment, supplies, personnel and
procedures for the storage, compounding and dispensing of drugs or devices, and
for the monitoring of drug therapy;</p>

<p class=MsoNormal style='line-height:150%'>     (11) The inspection of any
pharmacy practice site at all reasonable hours for the purpose of determining
if any provisions of the laws governing the legal distribution of drugs or
devices or the practice of pharmacy are being violated.  The board, its
officers, inspectors and representatives shall cooperate with all agencies
charged with the enforcement of the laws of the United States, of this State,
and of all other states relating to drugs, devices and the practice of
pharmacy;</p>

<p class=MsoNormal style='line-height:150%'>     (12) The inspection of
prescription files and the prescription records of a pharmacy and the removal
from the files and taking possession of any original prescription, providing
that the authorized agent removing or taking possession of an original
prescription shall place in the file from which it was removed a copy certified
by that person to be a true copy of the original prescription removed; provided
further, that the original copy shall be returned by the board to the file from
which it was removed after it has served the purpose for which it was removed;</p>

<p class=MsoNormal style='line-height:150%'>     (13) The establishment of
requirements for patient counseling, patient profiles and drug utilization
reviews;</p>

<p class=MsoNormal style='line-height:150%'>     (14) The establishment of
regulations to protect the health and safety of pharmacy patients; <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>and<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> </p>

<p class=MsoNormal style='line-height:150%'>     (15) The prescribing or
changing of the fees for examinations, certifications, licensures, renewals and
other services performed pursuant to P.L.1974, c.46 (C.45:1-3.1 et seq.) and
this act<u>; and</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(16)</u> <u> (a) Together
with the Division of Medical Assistance and Health Services in the Department
of Human Services, the establishment of educational, training, and
credentialing requirements for pharmacists to engage in comprehensive
medication management services for medically complex pediatric patients who are
enrolled in the NJ FamilyCare program;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(b)  As used in this
paragraph:</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>Clinical pharmacist means
a licensed pharmacist who has completed a clinical residency to acquire
expertise in the therapeutic use of medications to ensure optimal patient
health outcomes.  Clinical pharmacists work as part of a patients healthcare
professional team to provide medication therapy evaluations and recommendations
to patients and healthcare professionals.  </u></p>

<p class=MsoNormal style='line-height:150%'>     <u>Comprehensive medication
management services means a standard of care that ensures that a patients
medications, including prescription and nonprescription medications, vitamins,
or nutritional supplements, are individually assessed to determine whether each
medication is: appropriate for the patient, effective for the patients medical
condition, safe given the patients comorbidities and other medications being
taken, and able to be taken by the patient as intended.  Comprehensive
medication management services are provided by a clinical pharmacist as part of
a patients healthcare professional team.</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>NJ FamilyCare means the
program established pursuant to P.L.2005, c.156 (C.30:4J-8 et al.), which
includes the State's Medicaid Program and the Children's Health Insurance
Program</u> .</p>

<p class=MsoNormal style='line-height:150%'>     b.    The board shall have
those other duties, powers and authority as may be necessary to the enforcement
of this act and to the enforcement of rules and regulations of the board, which
may include, but not be limited to, the following:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  The determination and
issuance of standards, recognition and approval of degree programs of schools
and colleges of pharmacy whose graduates shall be eligible for licensure in
this State, and the specifications and enforcement of requirements for
practical training, including internships;</p>

<p class=MsoNormal style='line-height:150%'>     (2)  The registration of
externs, interns, pharmacy preceptors and pharmacy technicians;</p>

<p class=MsoNormal style='line-height:150%'>     (3)  The regulation of the
training, qualifications and conduct of applicants, externs, interns, pharmacy
preceptors and pharmacy technicians;</p>

<p class=MsoNormal style='line-height:150%'>     (4)  The collection of
professional demographic data;</p>

<p class=MsoNormal style='line-height:150%'>     (5)  The joining with those
professional organizations and associations organized to promote the improvement
of the standards of the practice of pharmacy for the protection of the health
and welfare of the public or whose activities assist and facilitate the work of
the board;</p>

<p class=MsoNormal style='line-height:150%'>     (6)  The establishment of a
bill of rights for patients concerning the health care services a patient may
expect in regard to pharmaceutical care;</p>

<p class=MsoNormal style='line-height:150%'>     (7)  The engagement in
activities to educate consumers, to assist them in obtaining information
necessary to make decisions about medication issues;</p>

<p class=MsoNormal style='line-height:150%'>     (8)  The establishment of
standards for the continuing education of registered pharmacists;</p>

<p class=MsoNormal style='line-height:150%'>     (9)  The establishment of
rules and regulations for extraordinary emergency situations that interfere
with the ability to practice under the current rules and regulations;</p>

<p class=MsoNormal style='line-height:150%'>     (10) The establishment of
guidelines for board approved pilot programs.  The guidelines shall be complied
with to implement a program that may not be presently acknowledged in this act
or its rules or regulations; and</p>

<p class=MsoNormal style='line-height:150%'>     (11) The assurance that any
credentialing or certification of a pharmacist is not misleading to the public.<br
clear=all style='page-break-before:always'>
</p>

<p class=MsoNormal style='line-height:150%'>     c.  (1) The board may place
under seal all drugs, biologicals, radio pharmaceuticals or devices that are
owned by or in the possession, custody or control of a licensee or permit
holder at the time his license or permit is suspended or revoked or at the time
the board refused to renew his license.  Except as otherwise provided in this
section, drugs, biologicals, radio pharmaceuticals or devices that are sealed
pursuant to this paragraph shall not be disposed of until appeal rights under
the &quot;Administrative Procedure Act,&quot; P.L.1968, c.410 (C.52:14B-1 et
seq.) have expired, or an appeal filed pursuant to that act has been
determined.  The court, involved in an appeal filed pursuant to the
&quot;Administrative Procedure Act,&quot; may order the board, during the
pendency of the appeal, to sell sealed drugs, biologicals and radio
pharmaceuticals that are perishable.  The proceeds of a sale shall be deposited
with the court.</p>

<p class=MsoNormal style='line-height:150%'>     (2)  Notwithstanding any
provisions of this act to the contrary, whenever a duly authorized
representative of the board finds, or has probable cause to believe, that any
drug or device is outdated, adulterated or misbranded within the meaning of the
&quot;Federal Food, Drug, and Cosmetic Act,&quot; 21 U.S.C.s.301 et seq., the
representative shall affix to that drug or device a tag or other appropriate
marking giving notice that the article is or is suspected of being outdated,
adulterated or misbranded, had been detained or embargoed, and warning all
persons not to remove or dispose of the article by sale or otherwise until
provision for removing or disposal is given by the board, its agent or the
court.  No person shall remove or dispose of an embargoed drug or device by
sale or otherwise without the permission of the board or its agent or, after
summary proceedings have been instituted, without permission of the court.</p>

<p class=MsoNormal style='line-height:150%'>     (3)  When a drug or device
detained or embargoed under paragraph (2) of this subsection c. has been
declared by the representative to be outdated, adulterated or misbranded, the
board shall, as soon as practical thereafter, petition the judge of the court
in which jurisdiction the article is detained or embargoed for an order for
condemnation of that article.  If the judge determines that this drug or device
so detained or embargoed is not adulterated, outdated or misbranded, the board
shall direct the immediate removal of the tag or other marking.</p>

<p class=MsoNormal style='line-height:150%'>     (4)  If the court finds that a
detained or embargoed drug or device is adulterated, outdated or misbranded,
that drug or device, after entry of the decree, shall be destroyed at the
expense of the owner under the supervision of a board representative and all
court costs and fees, storage and other proper expenses shall be borne by the
owner of that drug or device.  When the outdating, adulteration or misbranding
can be corrected by proper labeling or processing of the drug or device, the
court, after entry of the decree and after the costs, fees and expenses have
been paid and a good and sufficient bond has been posted, may direct that the
drug or device be <br clear=all style='page-break-before:always'>
delivered to the owner thereof for labeling or processing under the supervision
of a board representative.  Expense of that supervision shall be paid by the
owner.  The bond shall be returned to the owner of the drug or device on
representation to the court by the board that the drug or device is no longer
in violation of the embargo and the expense of supervision has been paid.</p>

<p class=MsoNormal style='line-height:150%'>     d.    Except as otherwise
provided to the contrary, the board shall exercise all of its duties, powers
and authority in accordance with the &quot;Administrative Procedure Act,&quot;
P.L.1968, c.410 (C.52:14B-1 et seq.).</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2003, c.280, s.9)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     3.    Section 25 of P.L.2003,
c.280 (C.45:14-64) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     25.  The provisions of this
act regulating collaborative drug therapy management shall not apply to <u>:</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>a.</u>    any pharmacist
practicing in a hospital, provided that prescribing within these institutions
takes place under the guidance of a pharmacy and therapeutics committee in
accordance with procedures as determined by regulations jointly promulgated by
the board and the State Board of Medical Examiners <u>; and</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>b.</u>    <u>a clinical
pharmacist authorized to provide comprehensive medication management to a
medically complex pediatric patient, pursuant to the provisions of P.L.    ,
c.     (C.        ) (pending before the Legislature as this bill)</u>.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2003, c.280, s.25)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     4.    (New section)  The
Commissioner of Human Services shall apply for such State plan amendments or waivers
as may be necessary to implement the provisions of section 1 of P.L.    ,
c.     (C.        ) (pending before the Legislature as this bill) and to secure
federal reimbursement for State Medicaid expenditures under the federal
Medicaid program.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     5.    (New section)  The
Commissioner of Human Services and the New Jersey State Board of Pharmacy shall,
in accordance with the &quot;Administrative Procedure Act,&quot; P.L.1968,
c.410 (C.52:14B-1 et seq.), adopt rules and regulations as necessary to
implement this act.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     6.  This act shall take effect
on the first day of the six month next following the date of enactment.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:150%'>STATEMENT</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     This bill requires the NJ
FamilyCare program to provide reimbursement for comprehensive medication
management (CMM) services when provided by a licensed clinical pharmacist for a
medically complex pediatric patient.  CMM services is defined as a standard
of care by which a clinical pharmacist assesses each of a patients medications,
including prescription and nonprescription medications, vitamins, and
nutritional supplements, to determine that each is appropriate, effective, and
safe, given the patients medical conditions, comorbidities, and other
medications.  Comprehensive medication management services are provided by a
clinical pharmacist as part of a patients health care team.</p>

<p class=MsoNormal style='line-height:150%'>     The bill defines a clinical
pharmacist as a licensed pharmacist who has completed a clinical residency to acquire
expertise in the therapeutic use of medications to ensure optimal patient
health outcomes.  Clinical pharmacists work as part of a patients team of healthcare
professionals to provide medication therapy evaluations and recommendations to
patients and healthcare providers.</p>

<p class=MsoNormal style='line-height:150%'>     CMM services for which a clinical
pharmacist would receive NJ FamilyCare reimbursement will include:</p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;line-height:150%'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span>comprehensive
reviews of a pediatric patients prescription medications, over-the-counter
medications, vitamins, and nutritional supplements;</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;line-height:150%'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span>development
and implementation of patient-specific medication action plans;</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;line-height:150%'>3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span>ongoing monitoring
of patient adherence to the patient-specific medication action plan;</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;line-height:150%'>4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span>follow-up
consultations and services necessary to ensure the efficacy and safety of the patient-specific
medication action plan; and</p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;line-height:150%'>5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span>any other CMM
services deemed necessary by the Division of Medical Assistance and Health
Services (the division) in the Department of Human Services and the Board of
Pharmacy for the appropriate care of a medically complex pediatric patient.</p>

<p class=MsoNormal style='line-height:150%'>     The bill directs the division to
enter into value-based contracts with licensed clinical pharmacists in order to
reimburse for CMM services provided for medically complex pediatric patients.  The
division also will establish a quality assurance program in order to monitor
and evaluate the outcomes and efficacy of the CMM services provided, and ensure
that these services align with the divisions value-based payment strategies.</p>

<p class=MsoNormal style='line-height:150%'>     The division and the New
Jersey State Board of Pharmacy in the Division of Consumer Affairs will designate
the educational, training, and credentialing requirements for licensed clinical
pharmacists to provide CMM services. </p>

<p class=MsoNormal style='line-height:150%'>     The bill also amends The New
Jersey Pharmacy Practice Act, P.L.2003, c.280 (C.45:14-40 et seq.), to specify
that a licensed clinical pharmacist who satisfies the credentialing requirements
for the provision of CMM services will not be required to enter into a written
agreement with a licensed physician in order to provide CMM services.  The bill
further amends section 25 of P.L.2003, c.280 to provide that the statutory
provisions regulating collaborative drug therapy management will not apply to
the provision of CMM services, as provided by a licensed clinical pharmacist. </p>

</div>

</body>

</html>
